Gamma-aminobutyric acid type A receptor alpha-2 and alpha-3 subunit-containing benzodiazepine binding sites (GABA_A alpha-2/alpha-3)

The GABA_A receptor alpha-2/alpha-3-containing benzodiazepine sites are specific pharmacological targets within the central nervous system responsible for mediating anxiolytic and analgesic effects. These receptors are heteropentameric ligand-gated ion channels that facilitate the influx of chloride ions upon GABA binding, leading to neuronal hyperpolarization and inhibition (Rudolph & Knoflach, 2011). While traditional benzodiazepines non-selectively target alpha-1, alpha-2, alpha-3, and alpha-5 subunits, the alpha-2 and alpha-3 subtypes are specifically localized in brain regions like the amygdala and the spinal cord's dorsal horn (Mohler, 2012). Targeting these specific subunits allows for the dissociation of therapeutic effects from the sedative and amnestic side effects primarily driven by the alpha-1 subunit (Atack, 2011). Consequently, selective positive allosteric modulators (PAMs) of alpha-2/alpha-3 sites are being developed as next-generation treatments for generalized anxiety disorder and chronic neuropathic pain (Griebel & Guiard, 2013). These agents aim to provide the rapid-acting efficacy of benzodiazepines without the associated risks of cognitive impairment, motor incoordination, or high abuse potential. Current research, including trials for compounds like darigabat, continues to explore the clinical utility of this subtype-selective approach (Cerevel Therapeutics, 2024).

Other names

alpha2/alpha3-GABA_A receptorsalpha2/alpha3-selective benzodiazepine sitesGABA_A receptor alpha-2 subunitGABA_A receptor alpha-3 subunitBZD sites on alpha2/alpha3 GABA_A receptors

Positive allosteric modulation (PAM) of the GABA_A receptor at the benzodiazepine binding site, specifically targeting receptors containing alpha-2 or alpha-3 subunits to increase chloride channel opening frequency in the presence of GABA (Atack, 2011; Rudolph & Knoflach, 2011).